Body surface area is an independent factor contributing to the effects of lamivudine treatment

Makoto Nakamuta, Kazuhiro Kotoh, Yuichi Tanabe, Eiji Kajiwara, Junya Shimono, Akihide Masumoto, Toshihiro Maruyama, Norihiro Furusyo, Hideyuki Nomura, Hironori Sakai, Kazuhiro Takahashi, Koichi Azuma, Shinji Shimoda, Munechika Enjoji, Jun Hayashi, R. Sugimoto, H. Amagase, S. Tominaga, K. Yanagita, K. OgiwaraM. Tokumatsu, S. Tabata, M. Yokota, H. Tanaka, S. Nagase, S. Tsuruta, S. Tada, M. Nagano, M. Honda, T. Umeno, T. Sugimura, S. Ueno, K. Miki, H. Okubo, H. Fujimoto, N. Higuchi, S. Shigematsu, N. Higashi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: It has been suggested that lamivudine therapy may be even more effective if administered at higher doses than is dictated by the current standard regimen. We analyzed the correlation between the effects of lamivudine and body surface area (BSA). Method: We evaluated 134 patients with chronic hepatitis B who had been treated with lamivudine for more than 12 months. The effect of the treatment was evaluated from the levels of serum alanine aminotransferase (ALT) and HBV-DNA. Several variables that could influence the response to treatment, including ALT, albumin, and bilirubin levels, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: Univariate logistic analysis selected platelet counts, BSA, HBV-DNA and HBeAg in the biological evaluation, and bilirubin, BSA, HBV-DNA and HBeAg in the virological evaluation (x2 > 1.0). Using these factors, multivariate analysis revealed that BSA (x2 = 12.8, p = 0.0004) was the only factor that could contribute significantly to the improvement of ALT levels, and that BSA (x2 = 4.4, p = 0.0354) and HBeAg (x2 = 8.1, p = 0.0044) were independent factors that could influence the suppression of HBV-DNA. Conclusion: We revealed that BSA is a significantly predictor of the effect of lamivudine therapy, suggesting that lamivudine dosage should be based on the individual BSA.

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalHepatology Research
Volume31
Issue number1
DOIs
Publication statusPublished - Jan 1 2005

Fingerprint

Lamivudine
Body Surface Area
Hepatitis B e Antigens
Alanine Transaminase
DNA
Therapeutics
Platelet Count
Bilirubin
Chronic Hepatitis B
Statistical Factor Analysis
Albumins
Multivariate Analysis
Serum

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Nakamuta, M., Kotoh, K., Tanabe, Y., Kajiwara, E., Shimono, J., Masumoto, A., ... Higashi, N. (2005). Body surface area is an independent factor contributing to the effects of lamivudine treatment. Hepatology Research, 31(1), 13-17. https://doi.org/10.1016/j.hepres.2004.11.004

Body surface area is an independent factor contributing to the effects of lamivudine treatment. / Nakamuta, Makoto; Kotoh, Kazuhiro; Tanabe, Yuichi; Kajiwara, Eiji; Shimono, Junya; Masumoto, Akihide; Maruyama, Toshihiro; Furusyo, Norihiro; Nomura, Hideyuki; Sakai, Hironori; Takahashi, Kazuhiro; Azuma, Koichi; Shimoda, Shinji; Enjoji, Munechika; Hayashi, Jun; Sugimoto, R.; Amagase, H.; Tominaga, S.; Yanagita, K.; Ogiwara, K.; Tokumatsu, M.; Tabata, S.; Yokota, M.; Tanaka, H.; Nagase, S.; Tsuruta, S.; Tada, S.; Nagano, M.; Honda, M.; Umeno, T.; Sugimura, T.; Ueno, S.; Miki, K.; Okubo, H.; Fujimoto, H.; Higuchi, N.; Shigematsu, S.; Higashi, N.

In: Hepatology Research, Vol. 31, No. 1, 01.01.2005, p. 13-17.

Research output: Contribution to journalArticle

Nakamuta, M, Kotoh, K, Tanabe, Y, Kajiwara, E, Shimono, J, Masumoto, A, Maruyama, T, Furusyo, N, Nomura, H, Sakai, H, Takahashi, K, Azuma, K, Shimoda, S, Enjoji, M, Hayashi, J, Sugimoto, R, Amagase, H, Tominaga, S, Yanagita, K, Ogiwara, K, Tokumatsu, M, Tabata, S, Yokota, M, Tanaka, H, Nagase, S, Tsuruta, S, Tada, S, Nagano, M, Honda, M, Umeno, T, Sugimura, T, Ueno, S, Miki, K, Okubo, H, Fujimoto, H, Higuchi, N, Shigematsu, S & Higashi, N 2005, 'Body surface area is an independent factor contributing to the effects of lamivudine treatment', Hepatology Research, vol. 31, no. 1, pp. 13-17. https://doi.org/10.1016/j.hepres.2004.11.004
Nakamuta, Makoto ; Kotoh, Kazuhiro ; Tanabe, Yuichi ; Kajiwara, Eiji ; Shimono, Junya ; Masumoto, Akihide ; Maruyama, Toshihiro ; Furusyo, Norihiro ; Nomura, Hideyuki ; Sakai, Hironori ; Takahashi, Kazuhiro ; Azuma, Koichi ; Shimoda, Shinji ; Enjoji, Munechika ; Hayashi, Jun ; Sugimoto, R. ; Amagase, H. ; Tominaga, S. ; Yanagita, K. ; Ogiwara, K. ; Tokumatsu, M. ; Tabata, S. ; Yokota, M. ; Tanaka, H. ; Nagase, S. ; Tsuruta, S. ; Tada, S. ; Nagano, M. ; Honda, M. ; Umeno, T. ; Sugimura, T. ; Ueno, S. ; Miki, K. ; Okubo, H. ; Fujimoto, H. ; Higuchi, N. ; Shigematsu, S. ; Higashi, N. / Body surface area is an independent factor contributing to the effects of lamivudine treatment. In: Hepatology Research. 2005 ; Vol. 31, No. 1. pp. 13-17.
@article{0f038a6f7c5e47adad4273367169fa1f,
title = "Body surface area is an independent factor contributing to the effects of lamivudine treatment",
abstract = "Background: It has been suggested that lamivudine therapy may be even more effective if administered at higher doses than is dictated by the current standard regimen. We analyzed the correlation between the effects of lamivudine and body surface area (BSA). Method: We evaluated 134 patients with chronic hepatitis B who had been treated with lamivudine for more than 12 months. The effect of the treatment was evaluated from the levels of serum alanine aminotransferase (ALT) and HBV-DNA. Several variables that could influence the response to treatment, including ALT, albumin, and bilirubin levels, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: Univariate logistic analysis selected platelet counts, BSA, HBV-DNA and HBeAg in the biological evaluation, and bilirubin, BSA, HBV-DNA and HBeAg in the virological evaluation (x2 > 1.0). Using these factors, multivariate analysis revealed that BSA (x2 = 12.8, p = 0.0004) was the only factor that could contribute significantly to the improvement of ALT levels, and that BSA (x2 = 4.4, p = 0.0354) and HBeAg (x2 = 8.1, p = 0.0044) were independent factors that could influence the suppression of HBV-DNA. Conclusion: We revealed that BSA is a significantly predictor of the effect of lamivudine therapy, suggesting that lamivudine dosage should be based on the individual BSA.",
author = "Makoto Nakamuta and Kazuhiro Kotoh and Yuichi Tanabe and Eiji Kajiwara and Junya Shimono and Akihide Masumoto and Toshihiro Maruyama and Norihiro Furusyo and Hideyuki Nomura and Hironori Sakai and Kazuhiro Takahashi and Koichi Azuma and Shinji Shimoda and Munechika Enjoji and Jun Hayashi and R. Sugimoto and H. Amagase and S. Tominaga and K. Yanagita and K. Ogiwara and M. Tokumatsu and S. Tabata and M. Yokota and H. Tanaka and S. Nagase and S. Tsuruta and S. Tada and M. Nagano and M. Honda and T. Umeno and T. Sugimura and S. Ueno and K. Miki and H. Okubo and H. Fujimoto and N. Higuchi and S. Shigematsu and N. Higashi",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.hepres.2004.11.004",
language = "English",
volume = "31",
pages = "13--17",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Body surface area is an independent factor contributing to the effects of lamivudine treatment

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Tanabe, Yuichi

AU - Kajiwara, Eiji

AU - Shimono, Junya

AU - Masumoto, Akihide

AU - Maruyama, Toshihiro

AU - Furusyo, Norihiro

AU - Nomura, Hideyuki

AU - Sakai, Hironori

AU - Takahashi, Kazuhiro

AU - Azuma, Koichi

AU - Shimoda, Shinji

AU - Enjoji, Munechika

AU - Hayashi, Jun

AU - Sugimoto, R.

AU - Amagase, H.

AU - Tominaga, S.

AU - Yanagita, K.

AU - Ogiwara, K.

AU - Tokumatsu, M.

AU - Tabata, S.

AU - Yokota, M.

AU - Tanaka, H.

AU - Nagase, S.

AU - Tsuruta, S.

AU - Tada, S.

AU - Nagano, M.

AU - Honda, M.

AU - Umeno, T.

AU - Sugimura, T.

AU - Ueno, S.

AU - Miki, K.

AU - Okubo, H.

AU - Fujimoto, H.

AU - Higuchi, N.

AU - Shigematsu, S.

AU - Higashi, N.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: It has been suggested that lamivudine therapy may be even more effective if administered at higher doses than is dictated by the current standard regimen. We analyzed the correlation between the effects of lamivudine and body surface area (BSA). Method: We evaluated 134 patients with chronic hepatitis B who had been treated with lamivudine for more than 12 months. The effect of the treatment was evaluated from the levels of serum alanine aminotransferase (ALT) and HBV-DNA. Several variables that could influence the response to treatment, including ALT, albumin, and bilirubin levels, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: Univariate logistic analysis selected platelet counts, BSA, HBV-DNA and HBeAg in the biological evaluation, and bilirubin, BSA, HBV-DNA and HBeAg in the virological evaluation (x2 > 1.0). Using these factors, multivariate analysis revealed that BSA (x2 = 12.8, p = 0.0004) was the only factor that could contribute significantly to the improvement of ALT levels, and that BSA (x2 = 4.4, p = 0.0354) and HBeAg (x2 = 8.1, p = 0.0044) were independent factors that could influence the suppression of HBV-DNA. Conclusion: We revealed that BSA is a significantly predictor of the effect of lamivudine therapy, suggesting that lamivudine dosage should be based on the individual BSA.

AB - Background: It has been suggested that lamivudine therapy may be even more effective if administered at higher doses than is dictated by the current standard regimen. We analyzed the correlation between the effects of lamivudine and body surface area (BSA). Method: We evaluated 134 patients with chronic hepatitis B who had been treated with lamivudine for more than 12 months. The effect of the treatment was evaluated from the levels of serum alanine aminotransferase (ALT) and HBV-DNA. Several variables that could influence the response to treatment, including ALT, albumin, and bilirubin levels, platelet counts, BSA, HBV-DNA, and HBeAg were analyzed. Results: Univariate logistic analysis selected platelet counts, BSA, HBV-DNA and HBeAg in the biological evaluation, and bilirubin, BSA, HBV-DNA and HBeAg in the virological evaluation (x2 > 1.0). Using these factors, multivariate analysis revealed that BSA (x2 = 12.8, p = 0.0004) was the only factor that could contribute significantly to the improvement of ALT levels, and that BSA (x2 = 4.4, p = 0.0354) and HBeAg (x2 = 8.1, p = 0.0044) were independent factors that could influence the suppression of HBV-DNA. Conclusion: We revealed that BSA is a significantly predictor of the effect of lamivudine therapy, suggesting that lamivudine dosage should be based on the individual BSA.

UR - http://www.scopus.com/inward/record.url?scp=19944427252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944427252&partnerID=8YFLogxK

U2 - 10.1016/j.hepres.2004.11.004

DO - 10.1016/j.hepres.2004.11.004

M3 - Article

AN - SCOPUS:19944427252

VL - 31

SP - 13

EP - 17

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 1

ER -